USRE40832E1 - Viral obesity methods and compositions - Google Patents

Viral obesity methods and compositions Download PDF

Info

Publication number
USRE40832E1
USRE40832E1 US11/868,450 US86845007A USRE40832E US RE40832 E1 USRE40832 E1 US RE40832E1 US 86845007 A US86845007 A US 86845007A US RE40832 E USRE40832 E US RE40832E
Authority
US
United States
Prior art keywords
subject
obesity
vaccine
virus
vaccine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/868,450
Inventor
Richard L. Atkinson
Nikhil V. Dhurandhar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obetech LLC
Original Assignee
Obetech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obetech LLC filed Critical Obetech LLC
Priority to US11/868,450 priority Critical patent/USRE40832E1/en
Application granted granted Critical
Publication of USRE40832E1 publication Critical patent/USRE40832E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Definitions

  • More than one reissue application has been filed for the reissue of U.S. Pat. No. 6 , 664 , 050 .
  • the reissue applications are the present application and application Nos. 11 / 099 , 679 and 11 / 475 , 235 , all of which are divisional reissues of U.S. Pat. No. 6 , 644 , 050 .
  • This invention concern obesity in humans caused by viruses and methods and compositions for diagnosing, treating and preventing this disease.
  • the invention also concerns methods and compositions for reducing levels of triglycerides and cholesterol in humans.
  • the invention concerns methods and compositions for diagnosing whether obesity in a human is caused by a virus or whether a person is susceptible to becoming obese because of having been infected with and an obesity-causing virus, methods for testing or screening body fluids (e.g., donated human blood) for the presence of obesity-causing viruses, methods for treating and preventing viral obesity in humans, methods for preparing vaccine compositions for treating and preventing viral obesity in humans, such vaccine compositions themselves, and viruses which cause viral obesity in humans.
  • body fluids e.g., donated human blood
  • the invention concerns methods for reducing serum levels of triglycerides and cholesterol, including low-density-lipoprotein-associated cholesterol, in humans by administration thereto of a virus which causes viral obesity in humans.
  • Obesity is a serious disease of humans.
  • a person is clinically obese if he or she has excess adipose tissue. More particularly, for purposes of this application, a person is obese if the person's body mass index equals or exceeds 27 kg/m 2 and the person has excess adipose tissue.
  • the quantity of adipose tissue that is “excessive” is not well defined; but certainly greater than 25% of body weight as fat in a male and greater than 30% of body weight as fat in a female would be excessive.
  • Obesity has a number of known and suspected etiologies. See A. Sclafani, “Animal Models of Obesity: Classification and Characterization,” Int. J. Obesity 8, 491-508 (1984); G. A. Bray, “Classification and Evaluation of the Obesities,” Med. Clin. N. Am. 73, 161-184 (1989).
  • TG triglycerides
  • CHOL cholesterol
  • LDL-CHOL low-density-lipoprotein-associated cholesterol
  • Obesity in people who have the disease, is associated with physical, psychological, and social problems.
  • Complications of obesity include, among others, diabetes mellitus, hypertension, hyperlipoproteinemia, cardiac diseases (atherosclerotic disease, congestive heart failure), pulmonary diseases (sleep apnea, restrictive lung disease), cerebrovascular accidents, cancers (breast, uterus, colon, prostate), gall bladder disease (stones, infection), toxemia during pregnancy, risks during surgery (pneumonia, wound infection, thrombo-phlebitis), gout, decreased fertility, degenerative arthritis, and early mortality.
  • TG, CHOL and LDL-CHOL levels that in an infected population are reduced on the average compared to a control population of obese individuals who are not infected with a virus of interest
  • a group of persons e.g., more than about 10, preferably more than 50, and more preferably more than about 100
  • a mean cholesterol level that is reduced, as described above in this paragraph.
  • Such an adenovirus strain is a “candidate virus.” Then, to determine whether a candidate virus is one that causes obesity and reduced choletersol levels, the virus is tested by methods recongized in the art, by infecting a group of animals such as chickens, mice, rats or monkeys, with the virus in order to test the virus for the ability to cause obesity and reduce chlesterol levels on the average in the group of infected animals.
  • a candidate virus which on testing in a group of animals does cause obesity and reduce the average cholesterol level in the group, is one which causes obesity and reduced cholesterol levels in humans and provides a basis for developing methods and compositions for diagnosing and treating obesity, screening for obesity-causing virus, and reducing cholesterol levels, in humans as understood in the art and described more fully hereinafter. These methods and compositions using any obesity-causing, cholesterol reducing adenovirus that infects humans are encompassed by the present invention.
  • adenoviruses Ad-2 and Ad-31 which are available from the American Type Culture Collection (“ATCC”), do not cause obesity or reduce cholesterol levels in humans but that adenovirus Ad-36, which is also avaialable from the ATCC, and a variant thereof that we have isolated, adenovirus Ad-36p, do do so.
  • ATCC American Type Culture Collection
  • the invention is substantially isolated human adneovirus Ad-36P.
  • Substantially isolated is defined herein with reference to a sample of viruses that is in an in vitro system such as a culture, a plate on which culture is grown, a suspension in buffer or culture medium, a band on a gel, a pellet resulting from configuration of a suspension comprising virus, or the like and that comprises one or more variants of human adenovirus strain Ad-36 as available from the ATCC (Rockville, Md., USA) under accession no. VR-913.
  • strain Ad-36 as obtained from the ATCC comprises a number of variants of the virus.
  • One of these variants is adenovirus Ad-36P.
  • substantially isolated is meant that the virus is in an in vitro system as described above and, in the system, the ratio of the number of particles of Ad-36P to the number of particles of all variants of strain Ad-36 is greater than such ratio in strain Ad-36 obtainable from the ATCC under accession no. VR-913.
  • a sample of Ad-36P is an in vitro system will consist essentially of virus particles of that variant alone, as might be obtained for example by standard passaging at least three times of strain Ad-36 as obtained from the ATCC.
  • Ad-36p is readily available to the art, as it can be isolated from some humans who are obese and who have reduced cholesterol levels (as indicated above, in comparison with obese persons who are not infected with an obesity-causing, cholesterol-level-reducing adenovirus).
  • nucleotide sequence of cDNA that encodes the fiber protein of strain Ad-36p. This sequence further serves to identify the strain.
  • Ad-36P adenovirus Ad-36P to be surprisingly sensitive, and specifically more sensitive than Ad-36 as obtained from culture obtained from the ATCC, in detecting serum antibody that reacts with Ad-36.
  • Ad-36P when it infects a person, causes the person to become obese with an obesity characterized by TG, CHOL and LDL-CHOL levels that, on the average in the infected population, are reduced compared to obese persons who are not infected with obesity-causing virus and in fact, in some obese and infected individuals (typically ones who are not severely obese) are not elevated above the normal levels in persons who are not obese.
  • the invention is an anti-obesity vaccine which comprises as the active ingredient a composition selected from the group consisting of: (i) killed virus and inactivated live virus, wherein the corresponding live (non-inactivated) virus infects humans, and causes obesity and reduced cholesterol levels in individuals infected with the virus, (ii) a coat protein of the coat of such a virus; (iii) an immunogenic peptide with from about 6 to about 30 amino acids in a sequence which comprises the sequence of an epitope of such a coat protein; (iv) nucleic acid (DNA or RAN) with a sequence which encodes such a coat protein or such an immunogenic peptide; and (v) a non-pathogenic virus, such as a vaccinia virus or fowl-pox virus, which is genetically modified to have a modified coat protein which comprises in immunogenic position and orientation a segment with the sequence of a coat protein of a virus which infects humans and causes obesity and reduced cholesterol in infected
  • a composition
  • the various active ingredients in the vaccines of the invention are either immunogenic per se or provide in two in a vaccinated person protein or peptide which is immunogenic.
  • Peptides of 6-30 amino acids, to be rendered acceptably immunogenic might require modification by any of various techniques known in the art (e.g., conjugation with a large protein).
  • the various vaccines in accordance with the invention are all prepared by methods known in the art.
  • adenoviruses which can be the bases for an anti-obesity vaccine according to the invention, because they infect human and cause obesity and reduced cholesterol levels on the average in infected individuals (among these Ad-3p being the most preferred), hexon or fiber proteins, preferably the fiber protein, or segments of the fiber protein, as indicated above, can be used as the immunogen.
  • immunogenic with reference to an anti-obesity vaccine of the invention, is intended capability to provoke in a person to whom the vaccine is administered an immune response that yields neutralizing antibodies against an obesity-causing, live virus that might infect the person after administration of the vaccine.
  • the anti-obesity vaccines of the invention wherein the immunogenic component is live, inactivated virus, killed virus, coat protein per se, epitope-comprising coat protein segment, or coat protein (or epitope-comprising segment thereof) provided with use of a non-pathogenic, genetically modified carrier virus such as a vaccinia virus or a fowl pox virus, are prepared using methods well known in the art.
  • the vaccines will include carriers, excipients, adjuvants, antimicrobials, preservatives and the like as well understood in the art.
  • the vaccines will have suitable compositions, usually aqueous buffers, such as phosphate-buffered saline or the like, in which the active ingredient will be suspended along with, optionally, any of various immune-system stimulating adjuvants used in human vaccine preparations, antimicrobial compositions, and other compositions to stabilize the preparations. All compositions included with the vaccine preparation will be suitable for administration to humans.
  • the vaccine preparation may be stored in lyophilized form and then combined with solution soon before administration.
  • the vaccine preparation may be in solution, tablet or pill form optionally with an entire coating as understood in the art.
  • the concentration of active (immunogenic or immunogen-providing) component in solution with which it is administered typically will be between about 1 ng 1 ng/ml and about 1 mg/ml.
  • the anti-obesity vaccines of the invention will be administered intranasally, orally, or by injection intravenously, intramuscularly, subcutaneously or peritoneally.
  • Administration of the vaccines of the invention is to be under the guidance of a physician.
  • the anti-obesity vaccine is well within the skill of medical practitioners and will depend on a number of factors including the age of the person being treated, the urgency of the person's developing protective immunity, the status of the person's immune system, and other factors known to the skilled.
  • the vaccine typically will be administered in several steps in order to cause and maintain protective immunity against obesity-causing virus in the person being vaccinated.
  • there typically will be between one and about ten booster vaccinations separated by periods between about 1 week and 10 years.
  • a single dose of an anti-obesity vaccine of the invention (in solution form) will have a volume of between about 0.1 ml and 10 ml and, in any form, will have between about 1 ng and 10 mg of killed or inactivated obesity-causing virus, between about 1 ng and 10 mg of genetically modified, non-pathogenic virus, or between about 1 ng and 10 mg of coat protein (e.g,. fiber protein) or 6-30 amino acid peptide (in its form as modified to be immunogenic).
  • coat protein e.g,. fiber protein
  • 6-30 amino acid peptide in its form as modified to be immunogenic.
  • An anti-obesity vaccine of the invention wherein the active ingredient is nucleic acid, will also be a standard preparation for vaccines of that type.
  • the nucleic acid is into the immunogen but is expressed in vivo after administration of the vaccine as a peptide or protein which in turn is immunogenic.
  • Vaccines of this type will be administered by techniques known in the art for such vaccines (e.g., intramuscular injection). Dosing will also be according to procedures known in the art to cause and maintain protective immunity against viral obesity in the vaccinated individual.
  • an anti-obesity vaccine according to the invention may include active ingredients based on more than one obesity-causing virus (or the coat protein (e.g. fiber protein) or epitopic segments of the coat protein thereof).
  • the invention is a method of preventing obesity caused by a virus in a human susceptible thereto which comprises administering to the human an amount of an anti-obesity vaccine of the invention that is effective to raise and maintain a protective immune response against an obesity-causing adenovirus.
  • the invention entails a method of reducing the serum levels of triglyceride, (total) cholesterol and low-density-lipoprotein-associated cholesterol in a person with above normal serum levels thereof which comprises administering to the person an amount effective for such purpose of a liver virus which infects humans and causes obesity in infected individuals.
  • Normal serum levels are as follows: triglycerides (TG): less than 150 mg/dL; (total) cholesterol (CHOL): less than 200 mg/dL; low-density-lipoprotein-associated cholesterol (LDL-CHOL): less than 130 mg/dL.
  • TG triglycerides
  • CHOL total cholesterol
  • LDL-CHOL low-density-lipoprotein-associated cholesterol
  • the TG, CHOL and LDL-CHOL levels would be reduced to normal levels.
  • This method of the invention could especially advantageously be applied to persons who are at very high risk of complications or death from atherosclerotic disease or congestive heart failure because of high serum levels of triglyceride (hypertriglyceridemia) or cholesterol (hypercholesterolemia).
  • the method is carried out by administering the live virus, or a more preferably a fragment of the virus such as the E 1A fragment which is a well known fragment of adenoviruses, in a conventional medium that is accpetable for administration to humans, to the person being treated in one or more doses sufficient to infect the person with the virus.
  • the administration can be intranasal, oral, or by injection intravenously, subcutaneously, intramuscularly, or peritoneally.
  • E1A fragments may be delivered intracellularly in a person being treated by methods known in the art using innocuous viruses, such as vaccinia viruses or retroviruses (modified so as to be non-infectious).
  • the innocuous viruses used in accordance with the invention will have genomes that are modified to include DNA that encodes the E1A fragment in a position where the fragment will be expressed in cells of the individual that have been infected with the innocuous virus.
  • the innocuous virus, so modified will be administered to an individual being treated so as to infect the individual (and cells of the individual) with the virus.
  • DNA itself(in an appropriate solution) which comprises a segment that encodes the EIA fragment may be injected directly into an individual being treated to provide E1A intracellularly in the individual.
  • the invention entails methods for diagnosing whether a non-obese person is at risk of acquiring viral obesity, a method for diagnosing whether an obese person suffers from viral obesity, and a method of screening body fluids or organs and tissues (especially denoted blood or donated organs or tissues) for the presence of obesity-causing adenoviruses.
  • These methods of the invention comprise analyzing, by any conventional immunoanalytical or nucleic-acid probe hybridization based procedure, a sample of blood, other body fluid, feces, tissue or organ for the presence of antibody reflecting infection with the virus, the presence of a protein (e.g., a fiber protein) characteristic of the presence of the virus, or the presence of a nucleic acid fragment characteristic of the presence of the virus.
  • a protein e.g., a fiber protein
  • a person whose blood, other body fluids, feces, or tissues or organs has been or is infected with the virus but who is not obese will be at greater risk than a person who has not been or is not so infected of becoming obese on account of infection by the obesity-causing virus and might be treated early to slow or prevent the onset of the disease.
  • an obese person whose blood, other body fluids, feces, or tissues or organs has been or is infected with the virus can ascribe his or her obesity at least in part to infection will the obesity-causing virus and, for example, might suffer less severe psychological or social trauma by understanding that he or she is suffering from an obesity that is a conventional disease or may demand reimbursement from his or her insurance company for having a type of obesity that is a conventional disease, caused by infection with a disease-causing virus.
  • the immunoanalytical techniques that might be used in these methods are standard virus neutralization assay techniques or enzyme immunoassay techniques made possible by the availability of obesity-causing viruses identified and made available by the present invention.
  • Antibodies against these viruses or fragments thereof (e.g., fiber protein or fragments thereof), or proteins (or fragments thereof) from these viruses for use in these immunoassay techniques can be prepared by conventional techniques well known in the art.
  • nucleic acid probe hybridization assay techniques used in these methods of the invention will be standard techniques (optionally after amplification of DNA or RNA extracted from a sample of blood, other body fluid, feces, tissue or organ) using nucleic acid probes (and primers if amplification is employed) made available by the obesity-causing viruses identified and made available by the present invention.
  • the sequences of nucleic acids characteristic of these viruses can be determined by standard techniques once the viruses are conventionally isolated, and probes and primers that are specific for the viruses and that provide the basis for nucleic acid probes and primers that can be used in nucleic acid based assays for the viruses are prepared using conventional techniques on the basis of the sequences.
  • kits may be assembled to facilitate carrying out the methods for a particular virus or a plurality of them.
  • Serum cholesterol (total)(TG) is determined using fasting serum, 10 microliter samples, in a cholesterol-oxidase-peroxidase, method employing a kit from Sigma Chemical Co., St. Louis, Mo., USA (Cat No. 352-SOOP).
  • Serum triglyceride is determined using fasting serum, 10 microliter samples, in a glycerol-3-phosphate peroxidase method employing a kit from Sigma Chemical Co. (Cat. No. 339-50).
  • Serum high-density lipoprotein-associated cholesterol (HDL-CHOL) is determined using fasting serum with a kit from Sigma Chemical Co.
  • LDL-CHOL Low-density-lipoprotein-associated cholesterol
  • Ad-36 virus was obtained from the ATCC (American Type Culture Collection), Accession No. VR-913. The virus was grown in A549 bronchial human carcinoma cells (Wisconsin State Laboratory of Hygiene, University of Wisconsin, Madison, Wis., USA). Plaques were grown, and a single plaque was removed and used to reinfect a fresh batch of A549 cells. Plaques of this second passage were grown and again a single plaque was picked and used to reinfect another fresh batch of A549 cells. The resulting virus is Ad-36P.
  • Ad-36p showed a 2-to 4-fold greater titer for neutralizing antibodies than did Ad-36. This demonstrates the greater sensitivity of Ad-36p, as compared to Ad-36, in assaying serum for antibody against obesity-causing adenoviruses.
  • MEM Minimum Essential Media Eagle
  • M-0643 Minimum Essential Media Eagle
  • 1-glutamine fetal bovine serum
  • sodium bicarbonate v/v
  • pH 7.4 sodium bicarbonate
  • 5 to 10 microliters of virus stock solution is mixed with 8 ml of the medium and the mixture is pipetted into flasks with growing cells.
  • the flasks are incubated for 1 h at 37 deg. C. while shaking gently every 15 min. After 1 h, the medium is removed and replaced with fresh medium.
  • the flasks are then incubated at 37 deg. C.
  • the cells are grown over 7 to 8 days, until 90% of the cells show CPE.
  • the cell material and medium are then centrifuged at 1000 rpm for 15 min to eliminate cell debris.
  • the supernatant with virus e.g., Ad-36 or Ad-36P
  • Ad-36 or Ad-36P is again centrifuged at 1000 rpm for 10 min and then aliquoted into 2 ml cryovials for storage at ⁇ 70 deg. C. until use.
  • Fiber protein is isolated from virus in a two step procedure. First, virus is purified from supernatant (see Example 3) using CsCl gradient centrifugation, following the procedure described by Graham and Ludvik in Chapter 11 of Methods in Molecular Biology, Vol. 7: Gene transfer and Expression Protocols, E. J. Murray, ed., The Humana Press, Inc., Clifton, N.J. (1991). Then the fiber protein is isolated from the virus electrophoretically following Oostrum and Burnett, J. Virology, 56,439448 (1985) and Maizel et aL, Virology, 36, 115-125 (1968).
  • the electrophoretic band of fiber protein (approx. mol. wt. 60,000 daltons) is cut from the gel and the fiber protein can be isolated from the band by standard techniques.
  • a virus neutralization assay (serum neutralization assay) is used to assay serum for antibody reactive with adenovirus in serum of test subjects.
  • Serum is thawed and heat-inactivated for 30 min. at 56 deg. C.
  • the assay is carried out in standard 96-well microliter plates. Serial two fold dilutions (1:2 to 1:1024) are made with the medium that is the A549 growth medium described in Example 3 but lacks the fetal calf serum and sodium bicarbonate. 50 microliters of each dilution is added in duplicate to the wells of the plate. 50 microliters of virus suspension (100 TCID 50) is then added to each well. (TCID 50 is calculated by serially diluting viral stock solution and inoculating A549 cells with the dilutions to determine the reciprocal of the highest dilution of virus which causes CPE in 50% of the material inoculated). The plates are then incubated at 37 deg. C. for 1 hr.
  • A549 cell suspension containing approximately 20,000 cells
  • the plate is further incubated at 37 deg. C. for 12 days.
  • Crystal violet-ethanol is then added to each of the wells to fix and stain the cells and the plates are examined macroscopically for CPE;
  • the highest serum dilution with no CPE is the titer.
  • Controls used in the procedure are wells with no virus and wells with virus but no serum.
  • a back titration is carried out to confirm that appropriate virus dilutions were used.
  • Positive control is antisera to chicken adenovirus and human adenovirus. Presence of CPE with the virus and no CPE in the presence of serum is considered an indication of effective neutralization of the virus with antibody in serum, such that the serum is considered to have antibody against the virus.
  • a titer of 1:8 or greater is considered positive.
  • the foregoing assay was carried out on serum samples from 155 obese patients and 45 non-obese volunteers. 15-20% of the obese patients were positive for antibody. All of these had TG, CHOL, and LDL-CHOL within the normal ranges for non-obese people. The remaining obese people (antibody-negative) had, on the average, TG, CHOL and LDL-CHOL levels above the normal ranges for non-obese people. None of the non-obese volunteers was positive for antibody. The non-obese volunteers had, on the average, TG, CHOl and LDL-CHOL levels that were in the normal ranges for non-obese people.
  • Ad-36P virus is killed by adding 42 microliters of 37% formalin to 150 microliters of virus stock, then incubating the resulting composition at room temperature for 72 hours, and finally adding 15 microliters of 35% sodium bisulfite. Confirmation that the virus was killed is carried out by inoculating a culture of A549 cells with the final solution and determining that virus does not grow in the culture.
  • Nucleic acid from adenovirus Ad-36p was isolated and sequenced by a standard sequencing method.
  • the cDNA sequence encoding the fiber protein is as follows (SEQ ID NO:1): 5′-ATGTCAAAGAGGCTCCGGGTGGAAGATGACTT CAACCCCGTCT ACCCCTATGGCTACGCGCGGAATCAGAATATCCCCTTCCTCACT CCCCCCTTTGTCTCCTCCGATGGATTCCAAAACTTCCCCCCTGG GGTCCTGTCACTCAAACTGGCTGATCCATGTCTCACTC AAGGTG GGAGGGGGACTCACTGTAGAACAACAGTCTGGAAAACTGAGTG TGGATACTAAGGCACCCTTGCAAGTTGCAAATGACAACAAATT GGAGCTATCTTATGATGATCCATTTAAGGTAGAGAATAA CAAA CTTGGAATTAAAGCTGGCCATGGTTTAGCAGTTGTAACTAAAGA AAACACAAGTCTTCCTAGTCTAGTTGGAACACTTGTAGTTTTAA CTGGAAAAGGAATAGGTACTGGATCAAGTGCACATG GAGGAAC TATTGATGTAAGACTTGGTGA
  • the cDNA sequence of the Ad-36p genome was screened against all known cDNA sequences and two 25-base sequences and one 28-base sequence were found, all lying in the fiber-encoding sequence provided above in Example 7, that were unique to Ad-36p. These three sequences are as follows:
  • Sequence 3 above was employed a probe for AD-36p in a conventional nuclei acid probe hybridization assay of DNA isolated from four chickens, two of which had been infected with the virus and became obese and two of which had not been infected and were not obese. DNA hybridizing to the probe was observed with only the DNA from the two infected chickens.
  • the assay involved direct detection and was by capillary electrophoresis using laser-induced fluorescence for detection. More particularly, a replaceable polyacrylamide matrix was employed in the electrophoretic separation and detection employed a dual system with 5′-labeling of the oligo and thiazole orange intercalator in the buffer system. See Kolester et al., J. Chromatography B, 697, 189-194 (1997).
  • probes, and primers when amplification is also used of between about 15 and 30 bases in length are advantageously employed to provide suitable specificity and sensitivity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A source of viral induced obesity has been discovered. A virus known as AD-36Padenovirus type 36 has been found to be associated with obesity in both animals and humans. Diagnostic DNA sequences are presented so that DNA based tests for the presence of the obesity associated virus can be conducted.

Description

NOTICE
More than one reissue application has been filed for the reissue of U.S. Pat. No. 6,664,050. The reissue applications are the present application and application Nos. 11/099,679 and 11/475,235, all of which are divisional reissues of U.S. Pat. No. 6,644,050.
RELATED APPLICATION
This application is a continuation of patent application Ser. No. 09/056,153 filed Apr. 6, 1998, now U.S. Pat. No. 6,127,113, which claims the benefit of the provisional U.S. application Ser. No. 60/042,942 filed Apr. 4, 1997.
TECHNICAL FIELD
This invention concern obesity in humans caused by viruses and methods and compositions for diagnosing, treating and preventing this disease.
The invention also concerns methods and compositions for reducing levels of triglycerides and cholesterol in humans.
More particularly, the invention concerns methods and compositions for diagnosing whether obesity in a human is caused by a virus or whether a person is susceptible to becoming obese because of having been infected with and an obesity-causing virus, methods for testing or screening body fluids (e.g., donated human blood) for the presence of obesity-causing viruses, methods for treating and preventing viral obesity in humans, methods for preparing vaccine compositions for treating and preventing viral obesity in humans, such vaccine compositions themselves, and viruses which cause viral obesity in humans.
Further, the invention concerns methods for reducing serum levels of triglycerides and cholesterol, including low-density-lipoprotein-associated cholesterol, in humans by administration thereto of a virus which causes viral obesity in humans.
BACKGROUND OF THE INVENTION
Obesity is a serious disease of humans. A person is clinically obese if he or she has excess adipose tissue. More particularly, for purposes of this application, a person is obese if the person's body mass index equals or exceeds 27 kg/m2 and the person has excess adipose tissue. In the medical arts, the quantity of adipose tissue that is “excessive” is not well defined; but certainly greater than 25% of body weight as fat in a male and greater than 30% of body weight as fat in a female would be excessive.
Obesity has a number of known and suspected etiologies. See A. Sclafani, “Animal Models of Obesity: Classification and Characterization,” Int. J. Obesity 8, 491-508 (1984); G. A. Bray, “Classification and Evaluation of the Obesities,” Med. Clin. N. Am. 73, 161-184 (1989).
There is a strong positive corrleation of increased body weight with elevated serum levels of triglycerides (TG) and cholesterol (CHOL), including low-density-lipoprotein-associated cholesterol (LDL-CHOL). Thus, obesity, in its known forms, is often associated with elevated serum levels of these substances.
The prevalence of obesity is increasing worldwide. The prevalence in the US population remained essentially constant, at about 25%, from 1960 to 1980. The prevalence in the US population increased between 1980 and 1990 to more than 33% and continues to increase. About 90 million people in the US are obese today. Similar statistics prevail in the rest of the world.
Obesity, in people who have the disease, is associated with physical, psychological, and social problems. Complications of obesity include, among others, diabetes mellitus, hypertension, hyperlipoproteinemia, cardiac diseases (atherosclerotic disease, congestive heart failure), pulmonary diseases (sleep apnea, restrictive lung disease), cerebrovascular accidents, cancers (breast, uterus, colon, prostate), gall bladder disease (stones, infection), toxemia during pregnancy, risks during surgery (pneumonia, wound infection, thrombo-phlebitis), gout, decreased fertility, degenerative arthritis, and early mortality.
Psychological complications of obesity include poor self-image and poor body-image. These complications are due in part to the fact that obesity is socially disfavored.
The fact that obesity is socially disfavored also presents social problems for obese people. Among these is discrimination in jobs, education and marriage.
Clearly, there is a need for methods to treat or prevent obesity. Effective treatment or preventative methods likely vary among the obese depending on the etiology of the obesity which an individual has.
Thus, there is a need to understand further the various etiologies of obesity. Such understanding that will lead to methods and compositions to effectively treat or prevent the disease.
Further understanding of the etiologies of obesity also will lead to reduction in the prevalence of the social stigma associated with the disease, as it will allow the public at large to understand better than obesity is a disease which might afflict anyone and from which people do not choose to suffer. Such understanding also will allow obese persons to be convinced that they are unwilling victims of a disease, to understand through various diagnostic tests based on understanding of etiologies of the disease what the underlying cause of their obesity is, and in some cases to learn how to effectively treat the disease. Reduction in the prevalence of the social stigma associated with obesity and increased understanding among the obese concerning the disease will diminish the psychological complications and social problems which affect obese persons because of the disease.
Still further, understanding of the etiologies underlying obesity and the corresponding recognition that obesity is a disease eventually will lead medical insurance companies, which now at least in the United States typically do not recognize the condition as a disease, to recognize it as such and reimburse persons for diagnosis and treatment of it in the same way that the companies now do so for conditions that have long been recognized as diseases.
There has been speculation that one etiology of obesity in humans might be viral. A. Sclafani, supra. However, there has been no convincing evidence to support this speculation. Heretofore no virus has been identified as a cause of the disease in humans.
SUMMARY OF THE INVENTION
We have discussed that some obesity in humans is caused by viruses.
We have identified a human virus which infects or has infected about 15-20% of obese persons in the general population.
Further we have discussed that humans who suffer from viral obesity (i.e., obesity caused by a virus) have, on the average, significantly lower TG, CHOL and LDL-CHOL levels than persons who suffer from obesity that is not viral. In fact, the average TG, CHOL and LDL-CHOL levels of persons with viral obesity are within the normal ranges for persons who are not obese.
Our discoveries are bases for the various methods and compositions of the invention as described below in detail.
DETAILED DESCRIPTION OF THE INVENTION
We have found that certain adenoviruses, but not all adenoviruses, that infect humans cause obesity in humans that are infected therewith and, at the same time, lower the average TG, CHOL and LDL-CHOL levels in those who are infected.
Screening of human adenoviruses for those that cause obesity and “reduced cholesterol levels” (by which is meant herein TG, CHOL and LDL-CHOL levels that in an infected population are reduced on the average compared to a control population of obese individuals who are not infected with a virus of interest) in humans is done by methods known in the art. Namely, in a preferred method, first by antibody-screening a group of persons (e.g., more than about 10, preferably more than 50, and more preferably more than about 100) is identified who have been infected by a particular strain of adenovirus and who are both obese and have, as a group, a mean cholesterol level that is reduced, as described above in this paragraph. Such an adenovirus strain is a “candidate virus.” Then, to determine whether a candidate virus is one that causes obesity and reduced choletersol levels, the virus is tested by methods recongized in the art, by infecting a group of animals such as chickens, mice, rats or monkeys, with the virus in order to test the virus for the ability to cause obesity and reduce chlesterol levels on the average in the group of infected animals. A candidate virus, which on testing in a group of animals does cause obesity and reduce the average cholesterol level in the group, is one which causes obesity and reduced cholesterol levels in humans and provides a basis for developing methods and compositions for diagnosing and treating obesity, screening for obesity-causing virus, and reducing cholesterol levels, in humans as understood in the art and described more fully hereinafter. These methods and compositions using any obesity-causing, cholesterol reducing adenovirus that infects humans are encompassed by the present invention.
By applying the foregoing methods, we have found that human adenoviruses Ad-2 and Ad-31, which are available from the American Type Culture Collection (“ATCC”), do not cause obesity or reduce cholesterol levels in humans but that adenovirus Ad-36, which is also avaialable from the ATCC, and a variant thereof that we have isolated, adenovirus Ad-36p, do do so.
Thus, in one of its aspects, the invention is substantially isolated human adneovirus Ad-36P.
“Substantially isolated” is defined herein with reference to a sample of viruses that is in an in vitro system such as a culture, a plate on which culture is grown, a suspension in buffer or culture medium, a band on a gel, a pellet resulting from configuration of a suspension comprising virus, or the like and that comprises one or more variants of human adenovirus strain Ad-36 as available from the ATCC (Rockville, Md., USA) under accession no. VR-913.
We have found that strain Ad-36 as obtained from the ATCC comprises a number of variants of the virus. One of these variants is adenovirus Ad-36P. Thus, by “substantially isolated” is meant that the virus is in an in vitro system as described above and, in the system, the ratio of the number of particles of Ad-36P to the number of particles of all variants of strain Ad-36 is greater than such ratio in strain Ad-36 obtainable from the ATCC under accession no. VR-913.
Preferably, of course, a sample of Ad-36P is an in vitro system will consist essentially of virus particles of that variant alone, as might be obtained for example by standard passaging at least three times of strain Ad-36 as obtained from the ATCC.
Strain Ad-36p is readily available to the art, as it can be isolated from some humans who are obese and who have reduced cholesterol levels (as indicated above, in comparison with obese persons who are not infected with an obesity-causing, cholesterol-level-reducing adenovirus).
Herein below we present the nucleotide sequence of cDNA that encodes the fiber protein of strain Ad-36p. This sequence further serves to identify the strain.
We have discovered adenovirus Ad-36P to be surprisingly sensitive, and specifically more sensitive than Ad-36 as obtained from culture obtained from the ATCC, in detecting serum antibody that reacts with Ad-36.
Adenovirus Ad-36P, like Ad-36, when it infects a person, causes the person to become obese with an obesity characterized by TG, CHOL and LDL-CHOL levels that, on the average in the infected population, are reduced compared to obese persons who are not infected with obesity-causing virus and in fact, in some obese and infected individuals (typically ones who are not severely obese) are not elevated above the normal levels in persons who are not obese.
In another of its aspects, the invention is an anti-obesity vaccine which comprises as the active ingredient a composition selected from the group consisting of: (i) killed virus and inactivated live virus, wherein the corresponding live (non-inactivated) virus infects humans, and causes obesity and reduced cholesterol levels in individuals infected with the virus, (ii) a coat protein of the coat of such a virus; (iii) an immunogenic peptide with from about 6 to about 30 amino acids in a sequence which comprises the sequence of an epitope of such a coat protein; (iv) nucleic acid (DNA or RAN) with a sequence which encodes such a coat protein or such an immunogenic peptide; and (v) a non-pathogenic virus, such as a vaccinia virus or fowl-pox virus, which is genetically modified to have a modified coat protein which comprises in immunogenic position and orientation a segment with the sequence of a coat protein of a virus which infects humans and causes obesity and reduced cholesterol in infected individuals or a sequence of a peptide of from about 6 to about 30 amino acids in a sequnece which comprises the sequence of an epitope of a virus which infects humans and causes obesity and reduced cholesterol in infected individuals.
The various active ingredients in the vaccines of the invention are either immunogenic per se or provide in two in a vaccinated person protein or peptide which is immunogenic. Peptides of 6-30 amino acids, to be rendered acceptably immunogenic, might require modification by any of various techniques known in the art (e.g., conjugation with a large protein).
The various vaccines in accordance with the invention are all prepared by methods known in the art.
From the adenoviruses which can be the bases for an anti-obesity vaccine according to the invention, because they infect human and cause obesity and reduced cholesterol levels on the average in infected individuals (among these Ad-3p being the most preferred), hexon or fiber proteins, preferably the fiber protein, or segments of the fiber protein, as indicated above, can be used as the immunogen.
By the term “immunogenic,” with reference to an anti-obesity vaccine of the invention, is intended capability to provoke in a person to whom the vaccine is administered an immune response that yields neutralizing antibodies against an obesity-causing, live virus that might infect the person after administration of the vaccine.
The anti-obesity vaccines of the invention, wherein the immunogenic component is live, inactivated virus, killed virus, coat protein per se, epitope-comprising coat protein segment, or coat protein (or epitope-comprising segment thereof) provided with use of a non-pathogenic, genetically modified carrier virus such as a vaccinia virus or a fowl pox virus, are prepared using methods well known in the art. Thus, the vaccines will include carriers, excipients, adjuvants, antimicrobials, preservatives and the like as well understood in the art. Thus, in addition to the active ingredient, the vaccines will have suitable compositions, usually aqueous buffers, such as phosphate-buffered saline or the like, in which the active ingredient will be suspended along with, optionally, any of various immune-system stimulating adjuvants used in human vaccine preparations, antimicrobial compositions, and other compositions to stabilize the preparations. All compositions included with the vaccine preparation will be suitable for administration to humans. The vaccine preparation may be stored in lyophilized form and then combined with solution soon before administration. For oral administration, the vaccine preparation may be in solution, tablet or pill form optionally with an entire coating as understood in the art. The concentration of active (immunogenic or immunogen-providing) component in solution with which it is administered typically will be between about 1 ng 1 ng/ml and about 1 mg/ml.
The anti-obesity vaccines of the invention will be administered intranasally, orally, or by injection intravenously, intramuscularly, subcutaneously or peritoneally.
Administration of the vaccines of the invention is to be under the guidance of a physician.
Appropriate dosing of the anti-obesity vaccine is well within the skill of medical practitioners and will depend on a number of factors including the age of the person being treated, the urgency of the person's developing protective immunity, the status of the person's immune system, and other factors known to the skilled. The vaccine typically will be administered in several steps in order to cause and maintain protective immunity against obesity-causing virus in the person being vaccinated. Thus, after the primary vaccination, there typically will be between one and about ten booster vaccinations separated by periods between about 1 week and 10 years.
A single dose of an anti-obesity vaccine of the invention (in solution form) will have a volume of between about 0.1 ml and 10 ml and, in any form, will have between about 1 ng and 10 mg of killed or inactivated obesity-causing virus, between about 1 ng and 10 mg of genetically modified, non-pathogenic virus, or between about 1 ng and 10 mg of coat protein (e.g,. fiber protein) or 6-30 amino acid peptide (in its form as modified to be immunogenic).
An anti-obesity vaccine of the invention, wherein the active ingredient is nucleic acid, will also be a standard preparation for vaccines of that type. With vaccines of this type, the nucleic acidis into the immunogen but is expressed in vivo after administration of the vaccine as a peptide or protein which in turn is immunogenic. Vaccines of this type will be administered by techniques known in the art for such vaccines (e.g., intramuscular injection). Dosing will also be according to procedures known in the art to cause and maintain protective immunity against viral obesity in the vaccinated individual.
Note that an anti-obesity vaccine according to the invention may include active ingredients based on more than one obesity-causing virus (or the coat protein (e.g. fiber protein) or epitopic segments of the coat protein thereof).
In yet another aspect, the invention is a method of preventing obesity caused by a virus in a human susceptible thereto which comprises administering to the human an amount of an anti-obesity vaccine of the invention that is effective to raise and maintain a protective immune response against an obesity-causing adenovirus.
In still another aspect, the invention entails a method of reducing the serum levels of triglyceride, (total) cholesterol and low-density-lipoprotein-associated cholesterol in a person with above normal serum levels thereof which comprises administering to the person an amount effective for such purpose of a liver virus which infects humans and causes obesity in infected individuals.
“Normal” serum levels are as follows: triglycerides (TG): less than 150 mg/dL; (total) cholesterol (CHOL): less than 200 mg/dL; low-density-lipoprotein-associated cholesterol (LDL-CHOL): less than 130 mg/dL.
In a preferred application of this method of the invention, the TG, CHOL and LDL-CHOL levels would be reduced to normal levels.
This method of the invention could especially advantageously be applied to persons who are at very high risk of complications or death from atherosclerotic disease or congestive heart failure because of high serum levels of triglyceride (hypertriglyceridemia) or cholesterol (hypercholesterolemia).
The method is carried out by administering the live virus, or a more preferably a fragment of the virus such as the E 1A fragment which is a well known fragment of adenoviruses, in a conventional medium that is accpetable for administration to humans, to the person being treated in one or more doses sufficient to infect the person with the virus. The administration can be intranasal, oral, or by injection intravenously, subcutaneously, intramuscularly, or peritoneally.
Among the live viruses that can be employed in this method of the invention are obesity-causing, cholesterol-level-reducing, human adenoviruses, such as Ad-36 and Ad-36P, an the E1A fragments thereof. E1A fragments may be delivered intracellularly in a person being treated by methods known in the art using innocuous viruses, such as vaccinia viruses or retroviruses (modified so as to be non-infectious). The innocuous viruses used in accordance with the invention will have genomes that are modified to include DNA that encodes the E1A fragment in a position where the fragment will be expressed in cells of the individual that have been infected with the innocuous virus. The innocuous virus, so modified, will be administered to an individual being treated so as to infect the individual (and cells of the individual) with the virus. As described hereinabove, as known in the art, DNA itself(in an appropriate solution) which comprises a segment that encodes the EIA fragment may be injected directly into an individual being treated to provide E1A intracellularly in the individual.
In still another aspect, the invention entails methods for diagnosing whether a non-obese person is at risk of acquiring viral obesity, a method for diagnosing whether an obese person suffers from viral obesity, and a method of screening body fluids or organs and tissues (especially denoted blood or donated organs or tissues) for the presence of obesity-causing adenoviruses. These methods of the invention comprise analyzing, by any conventional immunoanalytical or nucleic-acid probe hybridization based procedure, a sample of blood, other body fluid, feces, tissue or organ for the presence of antibody reflecting infection with the virus, the presence of a protein (e.g., a fiber protein) characteristic of the presence of the virus, or the presence of a nucleic acid fragment characteristic of the presence of the virus.
As understood in the art, a person whose blood, other body fluids, feces, or tissues or organs has been or is infected with the virus but who is not obese will be at greater risk than a person who has not been or is not so infected of becoming obese on account of infection by the obesity-causing virus and might be treated early to slow or prevent the onset of the disease. Similarly, an obese person whose blood, other body fluids, feces, or tissues or organs has been or is infected with the virus can ascribe his or her obesity at least in part to infection will the obesity-causing virus and, for example, might suffer less severe psychological or social trauma by understanding that he or she is suffering from an obesity that is a conventional disease or may demand reimbursement from his or her insurance company for having a type of obesity that is a conventional disease, caused by infection with a disease-causing virus. Also, the risk of spreading viral obesity to persons who are not infected with obesity-causing virus would be drastically reduced by screening of blood by blood banks, of blood that is donated for use by others than the donees, or screening of tissues or organs by tissue and organ banks or collecting agencies, of tissues or organs donated for transplantation, for the presence, past or present, of obesity-causing virus so that such blood, tissues or organs will not be used after having been donated.
The immunoanalytical techniques that might be used in these methods are standard virus neutralization assay techniques or enzyme immunoassay techniques made possible by the availability of obesity-causing viruses identified and made available by the present invention. Antibodies against these viruses or fragments thereof (e.g., fiber protein or fragments thereof), or proteins (or fragments thereof) from these viruses for use in these immunoassay techniques can be prepared by conventional techniques well known in the art.
Similarly, the nucleic acid probe hybridization assay techniques used in these methods of the invention will be standard techniques (optionally after amplification of DNA or RNA extracted from a sample of blood, other body fluid, feces, tissue or organ) using nucleic acid probes (and primers if amplification is employed) made available by the obesity-causing viruses identified and made available by the present invention. The sequences of nucleic acids characteristic of these viruses can be determined by standard techniques once the viruses are conventionally isolated, and probes and primers that are specific for the viruses and that provide the basis for nucleic acid probes and primers that can be used in nucleic acid based assays for the viruses are prepared using conventional techniques on the basis of the sequences.
As the skilled will understand, more than one strain of obesity-causing virus may be tested for simultaneously in an immunological or nucleic acid-based assay method for testing for virus in accordance with the invention and kits may be assembled to facilitate carrying out the methods for a particular virus or a plurality of them.
Further details on carrying out the inventor invention are now provided in the following examples, which are illustrative and should not be construed to limit the scope of the invention.
EXAMPLE 1
Serum cholesterol (total)(TG) is determined using fasting serum, 10 microliter samples, in a cholesterol-oxidase-peroxidase, method employing a kit from Sigma Chemical Co., St. Louis, Mo., USA (Cat No. 352-SOOP).
Serum triglyceride (TG) is determined using fasting serum, 10 microliter samples, in a glycerol-3-phosphate peroxidase method employing a kit from Sigma Chemical Co. (Cat. No. 339-50).
Serum high-density lipoprotein-associated cholesterol (HDL-CHOL) is determined using fasting serum with a kit from Sigma Chemical Co.
Low-density-lipoprotein-associated cholesterol (LDL-CHOL) is determined using the equation
LDL-CHOL=(CHO)-(HDL-CHO)-TG/5).
EXAMPLE 2
Ad-36 virus was obtained from the ATCC (American Type Culture Collection), Accession No. VR-913. The virus was grown in A549 bronchial human carcinoma cells (Wisconsin State Laboratory of Hygiene, University of Wisconsin, Madison, Wis., USA). Plaques were grown, and a single plaque was removed and used to reinfect a fresh batch of A549 cells. Plaques of this second passage were grown and again a single plaque was picked and used to reinfect another fresh batch of A549 cells. The resulting virus is Ad-36P.
In virus neutralization assays of 5 human sera known to have antibodies to Ad-36 (ATCC VR-913), Ad-36p showed a 2-to 4-fold greater titer for neutralizing antibodies than did Ad-36. This demonstrates the greater sensitivity of Ad-36p, as compared to Ad-36, in assaying serum for antibody against obesity-causing adenoviruses.
EXAMPLE 3
Minimum Essential Media Eagle (MEM)(Sigma Chemical Co. Cat. No. M-0643) with non-essential amino acids, Earle's salts, 1-glutamine, 10% fetal bovine serum and 2.9% sodium bicarbonate (v/v), pH 7.4, is used for growing A549 cells. 5 to 10 microliters of virus stock solution is mixed with 8 ml of the medium and the mixture is pipetted into flasks with growing cells. The flasks are incubated for 1 h at 37 deg. C. while shaking gently every 15 min. After 1 h, the medium is removed and replaced with fresh medium. The flasks are then incubated at 37 deg. C. The cells are grown over 7 to 8 days, until 90% of the cells show CPE. The cell material and medium are then centrifuged at 1000 rpm for 15 min to eliminate cell debris. The supernatant with virus (e.g., Ad-36 or Ad-36P), is again centrifuged at 1000 rpm for 10 min and then aliquoted into 2 ml cryovials for storage at −70 deg. C. until use.
EXAMPLE 4
Fiber protein is isolated from virus in a two step procedure. First, virus is purified from supernatant (see Example 3) using CsCl gradient centrifugation, following the procedure described by Graham and Ludvik in Chapter 11 of Methods in Molecular Biology, Vol. 7: Gene transfer and Expression Protocols, E. J. Murray, ed., The Humana Press, Inc., Clifton, N.J. (1991). Then the fiber protein is isolated from the virus electrophoretically following Oostrum and Burnett, J. Virology, 56,439448 (1985) and Maizel et aL, Virology, 36, 115-125 (1968).
The electrophoretic band of fiber protein (approx. mol. wt. 60,000 daltons) is cut from the gel and the fiber protein can be isolated from the band by standard techniques.
EXAMPLE 5
A virus neutralization assay (serum neutralization assay) is used to assay serum for antibody reactive with adenovirus in serum of test subjects.
Serum is thawed and heat-inactivated for 30 min. at 56 deg. C.
The assay is carried out in standard 96-well microliter plates. Serial two fold dilutions (1:2 to 1:1024) are made with the medium that is the A549 growth medium described in Example 3 but lacks the fetal calf serum and sodium bicarbonate. 50 microliters of each dilution is added in duplicate to the wells of the plate. 50 microliters of virus suspension (100 TCID50)is then added to each well. (TCID50 is calculated by serially diluting viral stock solution and inoculating A549 cells with the dilutions to determine the reciprocal of the highest dilution of virus which causes CPE in 50% of the material inoculated). The plates are then incubated at 37 deg. C. for 1 hr. Then 100 microliters of A549 cell suspension, containing approximately 20,000 cells, is added to each well and the plate is further incubated at 37 deg. C. for 12 days. Crystal violet-ethanol is then added to each of the wells to fix and stain the cells and the plates are examined macroscopically for CPE; The highest serum dilution with no CPE is the titer. Controls used in the procedure are wells with no virus and wells with virus but no serum. A back titration is carried out to confirm that appropriate virus dilutions were used. Positive control is antisera to chicken adenovirus and human adenovirus. Presence of CPE with the virus and no CPE in the presence of serum is considered an indication of effective neutralization of the virus with antibody in serum, such that the serum is considered to have antibody against the virus. A titer of 1:8 or greater is considered positive.
The foregoing assay was carried out on serum samples from 155 obese patients and 45 non-obese volunteers. 15-20% of the obese patients were positive for antibody. All of these had TG, CHOL, and LDL-CHOL within the normal ranges for non-obese people. The remaining obese people (antibody-negative) had, on the average, TG, CHOL and LDL-CHOL levels above the normal ranges for non-obese people. None of the non-obese volunteers was positive for antibody. The non-obese volunteers had, on the average, TG, CHOl and LDL-CHOL levels that were in the normal ranges for non-obese people.
EXAMPLE 6
Ad-36P virus is killed by adding 42 microliters of 37% formalin to 150 microliters of virus stock, then incubating the resulting composition at room temperature for 72 hours, and finally adding 15 microliters of 35% sodium bisulfite. Confirmation that the virus was killed is carried out by inoculating a culture of A549 cells with the final solution and determining that virus does not grow in the culture.
EXAMPLE 7
Nucleic acid from adenovirus Ad-36p was isolated and sequenced by a standard sequencing method.
The cDNA sequence encoding the fiber protein is as follows (SEQ ID NO:1): 5′-ATGTCAAAGAGGCTCCGGGTGGAAGATGACTT CAACCCCGTCT ACCCCTATGGCTACGCGCGGAATCAGAATATCCCCTTCCTCACT CCCCCCTTTGTCTCCTCCGATGGATTCCAAAACTTCCCCCCTGG GGTCCTGTCACTCAAACTGGCTGATCCATGTCTCACTC AAGGTG GGAGGGGGACTCACTGTAGAACAACAGTCTGGAAAACTGAGTG TGGATACTAAGGCACCCTTGCAAGTTGCAAATGACAACAAATT GGAGCTATCTTATGATGATCCATTTAAGGTAGAGAATAA CAAA CTTGGAATTAAAGCTGGCCATGGTTTAGCAGTTGTAACTAAAGA AAACACAAGTCTTCCTAGTCTAGTTGGAACACTTGTAGTTTTAA CTGGAAAAGGAATAGGTACTGGATCAAGTGCACATG GAGGAAC TATTGATGTAAGACTTGGTGAAGGAGGTGGGGTATCATTGAG AAAAAGGAGACTTAGTAGCTTGGGACAAAAAAAATGATACACG CACCCTTGGACAACACCTGATCCTTCTCCAAATTGC AAGTTG AAACAGCAAGAGACTCAAAGCTAACCTTAGCACTTACAAAATG TGGTAGTCAAATTTTGGCCACTGTATCTTTACTTGTTGTTACGGG CAAATATGCTATTATAAGTGACACAGTCAACCCAAAGCAGTTCT CTATTAAGTTACTGTTTAATGACAAGGGTGTTTTGTTAAGTGAC TCAAATCTTGATGGGACATATTGGAACTATAGAAGCAACAATA ACAACATAGGCACTCCTTATAAAGAGGCTGTTGGTTTTATGCCA AGCACAACAGCTTATCCTAAGCCAACCAACAACACCAGCACAG ATCCGGATAAAAAAGTGAGTCAAGGTAAAAATAAAAT TGTAAG CAATATATCTTGGAGGAGAGGTATATCAACCAGGATTTATTG TTGTTAAATTTAATCAGGAAACTGATGCCAATTGTGCATACTCT ATTACATTTGATTTGGATGGGGTAAGGTGTATAAGGA TCCTAT ACCATATGATACCTCTTCTACTTTCTCATATATCGCTCAAGA ATGA
EXAMPLE 8
The cDNA sequence of the Ad-36p genome was screened against all known cDNA sequences and two 25-base sequences and one 28-base sequence were found, all lying in the fiber-encoding sequence provided above in Example 7, that were unique to Ad-36p. These three sequences are as follows:
    • SEQ ID NO:2: 5′-AGTTGAAACAGCAAGAGACTCAAAG
    • SEQ ID NO:3 5′-GGTACTGGATCAAGTGCACATGGAG
    • SEQ ID NO:4 5′-TTGAAACAGCAAGAGACTCAAAGCTAAC
Sequence 3 above was employed a probe for AD-36p in a conventional nuclei acid probe hybridization assay of DNA isolated from four chickens, two of which had been infected with the virus and became obese and two of which had not been infected and were not obese. DNA hybridizing to the probe was observed with only the DNA from the two infected chickens. The assay involved direct detection and was by capillary electrophoresis using laser-induced fluorescence for detection. More particularly, a replaceable polyacrylamide matrix was employed in the electrophoretic separation and detection employed a dual system with 5′-labeling of the oligo and thiazole orange intercalator in the buffer system. See Kolester et al., J. Chromatography B, 697, 189-194 (1997).
The skilled will understand that probes, and primers when amplification is also used, of between about 15 and 30 bases in length are advantageously employed to provide suitable specificity and sensitivity.
Amplification methods using PCR and variations thereof maybe employed, as well known in the art.

Claims (24)

1. A method of determining whether an obese person is suffering from viral obesity caused by adenovirus type 36p, the method comprising the steps of isolating from the person a sample selected from the group consisting of a body fluid, feces, a sample of tissue and a sample of an organ from the person, obtaining an antibody specific to an adenovirus type 36p, and; assaying the sample using the antibody to test for the presence of the adenovirus type 36p thus testing whether the person has been or is infected with adenovirus type 36p, which causes obesity and reduces cholesterol level in humans.
2. The method according to claim 1 wherein the substance analyzed is blood.
3. A method for the detection of virally caused obesity in an obese subject comprising the steps of:
isolating a sample of biological tissue or fluid from the subject;
providing an antibody specific to adenovirus type 36p;
testing the sample, using the antibody diagnostic for adenovirus type 36p; and
detecting the presence of adenovirus type 36p to determine if the subject has viral induced obesity.
4. A method for preventing an adenovirus type 36 (Ad-36) infection in a subject, said method comprising the step of:
administering a vaccine composition including a immunogenically effective dose of an active compound selected from the group consisting of a killed Ad-36, an inactivated Ad-36, a protein or peptide sequence including an Ad-36 coat protein encoded by SEQ. ID. No: 1 or fragment thereof, and an Ad-36 E1A protein or a fragment thereof to the subject thereby stimulating the production of Ad-36 neutralizing antibodies in the subject such that the Ad-36 neutralizing antibodies prevent Ad-36 infection in the subject.
5. The method of claim 4, wherein the vaccine composition in said administering step is administered by one of intranasal administration, intramuscular injection, oral administration, intravenous administration, subcutaneous administration, and peritoneal administration.
6. The method of claim 4, wherein the subject is a human.
7. The method of claim 4, wherein the subject is a non-human animal.
8. The method of claim 4, wherein the administration of the vaccine composition is a primary vaccination.
9. The method of claim 8, further comprising the step of administering at least one booster vaccination after the primary vaccination to maintain protective immunity against Ad-36 in the vaccinated subject._L
10. The method of claim 4, wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml.
11. The method of claim 4, wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml and wherein the active compound is present in an amount in the range of about 1 ng/ml to about 10 ml/ml.
12. The method of claim 4, wherein the vaccine composition is a solution having a volume in the range of about 0.1 ml to about 10 ml and wherein the active ingredient is an Ad-36 coat protein or fragment thereof in an amount in the range of about 1 ng/ml to about 10 mg/ml.
13. The method of claim 12, wherein the Ad-36 coat protein fragment comprises a peptide having a length of about 6 amino acids to about 30 amino acids.
14. The method of claim 12, wherein the Ad-36 coat protein comprises an Ad-36 fiber protein or fragment thereof encoded by a nucleic acid selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 4.
15. The method of claim 4, wherein the vaccine composition is in a tablet form.
16. The method of claim 4, wherein the vaccine composition prevents Ad-36 induced obesity in the subject.
17. An adenovirus type 36 (Ad-36) vaccine composition suitable for administration to a subject comprising:
an active ingredient capable of stimulating the production of Ad-36 neutralizing antibodies in the subject, wherein the active compound is selected from the group consisting of a killed Ad-36, an inactivated Ad-36, a protein or peptide sequence including an Ad-36 coat protein encoded by SEQ. ID. No. 1 or fragment thereof, and an Ad-36 E1A protein or a fragment thereof; and
a pharmaceutically acceptable carrier.
18. The vaccine of claim 17, wherein the Ad-36 coat protein fragment is encoded by one or more nucleic acid sequences selected from the group consisting of SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No. 4.
19. The vaccine of claim 17, wherein said active compound has a concentration in the range of about 1 ng/ml to about 1 mg/ml.
20. The vaccine of claim 17, wherein said vaccine composition is in one of a solution, a capsule form, or a tablet form.
21. The vaccine of claim 17, wherein the subject is a human.
22. The vaccine of claim 17, wherein the subject is a non-human animal.
23. The vaccine of claim 17, wherein said vaccine composition is suitable for administration by a route selected from the group consisting of intranasally, orally, intravenously, intramuscularly, subcutaneously, and peritoneally.
24. The vaccine of claim 17, wherein said vaccine composition prevents Ad-36 induced obesity in the subject.
US11/868,450 1997-04-04 2007-10-05 Viral obesity methods and compositions Expired - Lifetime USRE40832E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/868,450 USRE40832E1 (en) 1997-04-04 2007-10-05 Viral obesity methods and compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4294297P 1997-04-04 1997-04-04
US09/056,153 US6127113A (en) 1997-04-04 1998-04-06 Viral obesity methods and compositions
US09/619,117 US6664050B1 (en) 1997-04-04 2000-07-19 Viral obesity methods and compositions
US11/868,450 USRE40832E1 (en) 1997-04-04 2007-10-05 Viral obesity methods and compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/619,117 Reissue US6664050B1 (en) 1997-04-04 2000-07-19 Viral obesity methods and compositions

Publications (1)

Publication Number Publication Date
USRE40832E1 true USRE40832E1 (en) 2009-07-07

Family

ID=21924579

Family Applications (6)

Application Number Title Priority Date Filing Date
US09/056,153 Expired - Lifetime US6127113A (en) 1997-04-04 1998-04-06 Viral obesity methods and compositions
US09/619,117 Ceased US6664050B1 (en) 1997-04-04 2000-07-19 Viral obesity methods and compositions
US11/099,679 Expired - Lifetime USRE39544E1 (en) 1997-04-04 2005-04-06 Viral obesity methods and compositions
US11/475,235 Expired - Lifetime USRE39914E1 (en) 1997-04-04 2006-06-27 Viral obesity methods and compositions
US11/868,450 Expired - Lifetime USRE40832E1 (en) 1997-04-04 2007-10-05 Viral obesity methods and compositions
US12/494,978 Expired - Lifetime USRE42129E1 (en) 1997-04-04 2009-06-30 Viral obesity methods and compositions

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US09/056,153 Expired - Lifetime US6127113A (en) 1997-04-04 1998-04-06 Viral obesity methods and compositions
US09/619,117 Ceased US6664050B1 (en) 1997-04-04 2000-07-19 Viral obesity methods and compositions
US11/099,679 Expired - Lifetime USRE39544E1 (en) 1997-04-04 2005-04-06 Viral obesity methods and compositions
US11/475,235 Expired - Lifetime USRE39914E1 (en) 1997-04-04 2006-06-27 Viral obesity methods and compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/494,978 Expired - Lifetime USRE42129E1 (en) 1997-04-04 2009-06-30 Viral obesity methods and compositions

Country Status (3)

Country Link
US (6) US6127113A (en)
AU (1) AU6884298A (en)
WO (1) WO1998044946A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087455A1 (en) * 2005-12-27 2009-04-02 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044946A1 (en) * 1997-04-04 1998-10-15 Obetech, Llc Viral obesity methods and compositions
US7674632B1 (en) * 2001-12-10 2010-03-09 Zeus Scientific, Inc Method and composition for homogeneous multiplexed microparticle-based assay
CA2574721C (en) * 2004-07-19 2011-06-07 Life Science Nutrition As Ngna compositions and methods of use
US7507418B2 (en) * 2005-09-09 2009-03-24 Obetech, Llc Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
WO2008073893A2 (en) * 2006-12-08 2008-06-19 Adv Technologies Llc Methods for producing an adenovirus type 5 gene transfer vector
US20100119558A1 (en) 2008-11-10 2010-05-13 Scandivir Ab Ngna compositions and methods of use
US8697670B2 (en) * 2009-01-28 2014-04-15 Life Science Nutrition As Compositions and methods of treating viral infections
US8585588B2 (en) 2009-11-18 2013-11-19 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
US20130052635A1 (en) * 2010-03-25 2013-02-28 Richard L. Atkinson Method For Detecting Lipogenic Adenovirus
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044946A1 (en) * 1997-04-04 1998-10-15 Obetech, Llc Viral obesity methods and compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dhurandhar et al, Antiviral Agents Bulletin, Apr. 1, 1997, abstract only. *
Dhurandhar et al. Apr. 1, 1997, FASEB, vol. 11, No. 3, pp. A230. *
Wigand et al, Archives of Virology, 1980, vol. 64, pp. 225-233. *
Wigand et al. 1980, Archives of Virology, vol. 64 (3), pp. 225-233 (abstract only). *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087455A1 (en) * 2005-12-27 2009-04-02 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
US7910310B2 (en) * 2005-12-27 2011-03-22 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
US20110189235A1 (en) * 2005-12-27 2011-08-04 Obetech, Llc Adipogenic Adenoviruses As A Biomarker For Disease
US20130323273A1 (en) * 2005-12-27 2013-12-05 Obetech, Llc Adipogenic Adenoviruses as a Biomarker for Disease

Also Published As

Publication number Publication date
USRE42129E1 (en) 2011-02-08
WO1998044946A1 (en) 1998-10-15
USRE39544E1 (en) 2007-04-03
US6664050B1 (en) 2003-12-16
USRE39914E1 (en) 2007-11-06
US6127113A (en) 2000-10-03
AU6884298A (en) 1998-10-30

Similar Documents

Publication Publication Date Title
USRE40832E1 (en) Viral obesity methods and compositions
US7442511B2 (en) Adipogenic adenoviruses as a biomarker for disease
US4777239A (en) Diagnostic peptides of human papilloma virus
Li et al. Characterization of self-assembled virus-like particles of human polyomavirus BK generated by recombinant baculoviruses
JPS62502378A (en) Type-specific papillomavirus DNA sequences and peptides
EP0428596B1 (en) Novel infectious bursal disease virus
JPS61289888A (en) Vaccinia dna
EA022213B1 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
JP3117695B2 (en) Method for preventing papilloma virus (HPV) in human body for medical purposes
CN1045603A (en) Screening system
US6284532B1 (en) Purified human papillomavirus
US5916570A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
US7507418B2 (en) Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
Epstein Vaccination against Epstein-Barr virus: current progress and future strategies
Embers et al. Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins
US5665533A (en) Skin test to human papillomavirus type 16
RU2290204C1 (en) Recombinant fused protein, preparation for immunotherapy based on thereof and method for immunotherapy of relapsing larynx papillomatosis
CA2113641A1 (en) Recombinant infectious bovine rhinotracheitis virus
Carlsson et al. Purification of infectious pancreatic necrosis virus by anion exchange chromatography increases the specific infectivity
KR100785397B1 (en) Recombinant adenoviral vector expressing HPV-like particles and live vaccine for cervical cancer prepared therefrom
WO1991008310A1 (en) Detection of human adenovirus
Winters et al. Incomplete human adenovirus replication in canine tumour cells and serological evidence of infections in tumour-bearing canine pets
US20100317567A1 (en) Diagnosing and protecting horses against papillomavirus
FR2601689A1 (en) Attenuated herpes viruses, herpes viruses containing foreign DNA which encodes an amino acid sequence, and vaccines containing them

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 8